University of Cambridge Milner Logo  



Executive Manager Dr Kathryn Chapman speaking at the Novo Nordisk Foundation earlier this month.

  Get connected with News@Milner

Welcome to the Milner Therapeutics Institute newsletter! The intention of this letter is to bring together the academic and industrial components of our Institute. Visit the Milner web site for further info »


Milner Update: February 2018


Earlier this month we announced our new partnership with LifeArc to identify and validate new drug targets in immuno-oncology and respiratory diseases. Under this collaborative project, we will be developing cutting-edge machine-learning approaches which will be integrated into drug discovery processes to enhance the design of key experiments to validate and prioritise targets. Read more »

With the Gurdon Institute, we will be co-hosting the next Cambridge New Therapeutics Forum which brings together academic, biotech and industry scientists researching new therapeutics in the Cambridge and the local area. It will be held in the Biochemistry Department on 20th March 2018, from 17.30-20.30. Register here »

We are recruiting!
Three exciting new opportunities to join the Milner Therapeutics Institute will be announced soon. Follow us on Twitter and LinkedIn to keep up to date with our latest recruitment news.

If you would like to order any copies of our new glossy brochure, please contact us at


Save the Date


Save the date: Milner Therapeutics Symposium 2018

Our third annual Milner Therapeutics Institute Symposium has been confirmed for 1st Oct 2018. This yearly networking event of 300+ scientists from biotech, pharma, CROs and academia is a fantastic opportunity to catalyse new partnerships and collaborations.


Affiliated Company Spotlight


Metrion Biosciences is a UK-based Contract Research Organization specialising in high quality ion channel screening and drug development expertise.

Metrion provides customers with access to a range of in vitro screening services that include cardiac safety (hERG, CiPA panel of human cardiac ion channels) and neurotoxicology testing and phenotypic assays on a fee-for-service or collaboration basis. Collectively, their management team have amassed over 80 years of experience in ion channel drug discovery and their clients can access this high level of expertise as part of their dedicated service.

Metrion have have been awarded £200,000 funding under the Innovate UK Biomedical Catalyst Feasibility Award scheme in 2018 which will enable further preclinical development activities to be undertaken on the portfolio of small molecule potassium inhibitors acquired by Metrion. The aim is to deliver a ‘best in class’, orally bioavailable, small molecule potassium channel inhibitor for the safe and effective treatment of a range of autoimmune diseases.

To find out more about Metrion, visit their website here »


Affiliated Company News


Charles River Acquires KWS BioTest Read more »

European Commission approves Amgen and Allergan's biosimilar bevacizumab for the treatment of certain types of cancer Read more »

Sphere Fluidics expands Cyto-Mine sales team and distribution in US, Europe and Asia Read more »

Selcia’s Fragment Library successfully used to generate hits for GPCR target using TR-FRET kinetic profiling method Read more »

Cell Guidance Systems launches SINEUP, a powerful new tool which allows researchers to simply, routinely and specifically "knock-up" or boost the levels of specific proteins Read more »

BTG OPTALYSE trial results reinforce safety and efficacy of shorter, lower dose EKOS therapy for pulmonary embolism Read more »

DefiniGEN announces collaboration with GenoMembrane to further develop iPS-derived intestinal organoids for drug absorption and transportation assay models Read more »

Diagenode and Genialis announce sample-to-analysis RNA-seq workflow for accurate differential expression analysis from low inputs Read more »

Eagle Genomics and the Stratified Medicine Scotland Innovation Centre (SMS-IC) have been awarded £1.7M from Innovate UK to develop new tests and treatments for patients with non-alcoholic fatty liver disease (NAFLD) Read more »

Genedata bioprocess licensed to Pfizer Read more »

Horizon Discovery enters into license agreement with US immuno-oncology company Read more »

Genedata Profiler™ powers major breakthroughs in early prediction of breast and ovarian cancer Read more »

Atrius Health leverages Linguamatics Natural Language Processing to support value-based care Read more »

Proximagen and Axxam enter into a strategic collaboration for the discovery of novel molecules against targets for CNS disorders, pain and inflammation Read more »

Repositive team grows by almost 50% in past year requiring move to newly refurbished premises on Hills Road, Cambridge Visit website»

Collaboration with AstraZeneca strengthens Charles River's high-throughput screening capabilities Read more »

Cancer Research UK and The Institute of Cancer Research, London, join forces with Merck in new drug discovery alliance Read more »

Molecular Devices & Abcam announce strategic collaboration Read more »

Abcam signs exclusive license agreement with Roche Read more »

Agilent Expands Cell Analysis Portfolio with acquisition of Luxcel Biosciences Read more »

Cyclofluidic is using CyclOps™, its proprietary integrated drug discovery platform, to accelerate early stage discovery projects for its partners Visit website »

STORM Therapeutics extends Series A Round to include new investor Taiho Ventures Read more »

Diagenode annouce new award-winning ChIPmentation Read more »

O2h to host The O2h Innovation Conference, March 2018, Ahmedabad, India Read more »




Drug Repurposing for Rare Diseases Conference 2018
27th February 2018, London

Bringing together patient groups, clinicians, researchers, and life science professionals, to discuss the latest developments in drug repurposing, and its role in the future of rare disease treatment. Read more »

Northern NIHR Biomedical Research Centres' Showcase
15th March, London

Hear from and network with renowned BRCs from across Cambridge, London and Oxford, find out about their successful projects and better understand the opportunities available to work collaboratively with the BRCs. Read more »

BioTrinity UK Biopartnering and Investment Conference
23rd - 25th April, London

The theme for BioTrinity 2018 is 'Next Generation Healthcare' which will be explored via a range of insightful keynote and panel discussions. Read more »

ELRIG Research and Innovation 2018: New Biology, New Targets
17th & 18th April 2018, Cambridge

The meeting will bring together world class speakers and leading academic and industry experts who will discuss the challenges and opportunities in the area of new technologies and novel targets to improve the success of drug discovery and to develop new therapeutic agents. Hear up-to-date views on this exciting and rapidly evolving area, including presentations on the latest advances and technology breakthroughs.Read more »

Linguamatics Spring Text Mining Conference
23rd April 2018, Cambridge

The conference provides new, experienced and potential users of Linguamatics I2E software an excellent opportunity to explore the latest trends in natural language processing-based text mining. Read more »

2018 Cambridge Ion Channel Forum
8th May, Cambridge

Metrion Biosciences and AstraZeneca will be co-hosting the fifth Cambridge Ion Channel Forum. Professor Peter McNaughton (King’s College London) will be giving the keynote presentation about his research into the role of HCN2 ion channels in pain. Read more »

Biotech Investment Showcase and Start Up Slam
22nd & 23rd May 2018, London

This event will help to identify key technological and scientific investment areas and offers a unique networking, partnering and business development opportunity. Read more »

The Pharma Business Development Course - An Overview Course
11th & 12th December 2018, London

Understand the structure of the pharma business development process – Grasp the terminology, challenges, concepts & tools in each step, from analysis and planning, to closing and following-up a deal – be prepared for the financial and legal pitfalls. Read more »




Senior Project Manager, Abcam. Read more »

Research Associate, Active Motif. Read more »

Director of Chemistry, BioAscent. Read more »

Director of Biosciences, BioAscent. Read more »

Commercial Development Manager, BTG. Read more »

Business Development Manager, Genedata. Read more »

Principal Scientist, Horizon Discoveries. Read more »

Contact us

The Milner Institute
University of Cambridge
Tennis Court Road
Cambridge CB2 1QN, UK
Tel: +44 (0)1223 767111 |

Subscribe | Unsubscribe